Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

Heather E. Wheeler1, Eric R. Gamazon2, Claudia Wing1, Uchenna O. Njiaju1, Chidiamara Njoku1; Robert Michael Baldwin3, Kouros Owzar4, Chen Jiang4, Dorothy Watson4, Ivo Shterev4, Michiaki Kubo5, Hitoshi Zembutsu5, Eric P. Winer6, Clifford A. Hudis7, Lawrence N. Shulman6, Yusuke Nakamura1,5, Mark J. Ratain1, and Deanna L. Kroetz3 for the Cancer and Leukemia Group B; Nancy J. Cox2, and Mary Eileen Dolan1

Abstract

Purpose: We sought to show the relevance of a lymphoblastoid cell line (LCL) model in the discovery of clinically relevant genetic variants affecting chemotherapeutic response by comparing LCL genome-wide association study (GWAS) results to clinical GWAS results.

Experimental Design: A GWAS of paclitaxel-induced cytotoxicity was conducted in 247 LCLs from the HapMap Project and compared with a GWAS of sensory peripheral neuropathy in patients with breast cancer (n = 855) treated with paclitaxel in the Cancer and Leukemia Group B (CALGB) 40101 trial. Significant enrichment was assessed by permutation resampling analysis.

Results: We observed an enrichment of LCL cytotoxicity-associated single-nucleotide polymorphisms (SNP) in the sensory peripheral neuropathy-associated SNPs from the clinical trial with concordant allelic directions of effect (empirical P = 0.007). Of the 24 SNPs that overlap between the clinical trial (P < 0.05) and the preclinical cytotoxicity study (P < 0.001), 19 of them are expression quantitative trait loci (eQTL), which is a significant enrichment of this functional class (empirical P = 0.0447). One of these eQTLs is located in RFX2, which encodes a member of the DNA-binding regulatory factor X family. Decreased expression of this gene by siRNA resulted in increased sensitivity of Neuroscreen-1 (NS-1; rat pheochromocytoma) cells to paclitaxel as measured by reduced neurite outgrowth and increased cytotoxicity, functionally validating the involvement of RFX2 in nerve cell response to paclitaxel.

Conclusions: The enrichment results and functional example imply that cellular models of chemotherapeutic toxicity may capture components of the underlying polygenic architecture of related traits in patients. Clin Cancer Res; 19(2); 491–9. ©2012 AACR.
Lympoblastoid cell lines (LCL) have been used in chemotherapeutic pharmacogenomic marker discovery due to their ease of experimental manipulation, extensive genotype catalogs, and lack of the in vivo confounders present in clinical samples. One important question is how well these cell-based models generate clinically relevant single-nucleotide polymorphisms (SNP) associated with patient toxicity. We compared genome-wide association study (GWAS) results of paclitaxel-induced cytotoxicity in LCLs and paclitaxel-induced peripheral neuropathy in patients with breast cancer. We observed significant overlap between the clinical and LCL studies, thus confirming a role for the LCL model in the analysis of at least a subset of genes involved in patient paclitaxel response. One overlap gene, RFX2, was functionally validated in a nerve cell model of paclitaxel response. Peripheral neuropathy is often dose-limiting toxicity induced by paclitaxel treatment. If physicians could predict which patients are more likely to experience this severe toxicity, lower doses or alternative treatments could be prescribed.

**Translational Relevance**

Lymphoblastoid cell lines (LCL) have been used in chemotherapeutic pharmacogenomic marker discovery due to their ease of experimental manipulation, extensive genotype catalogs, and lack of the in vivo confounders present in clinical samples. One important question is how well these cell-based models generate clinically relevant single-nucleotide polymorphisms (SNP) associated with patient toxicity. We compared genome-wide association study (GWAS) results of paclitaxel-induced cytotoxicity in LCLs and paclitaxel-induced peripheral neuropathy in patients with breast cancer. We observed significant overlap between the clinical and LCL studies, thus confirming a role for the LCL model in the analysis of at least a subset of genes involved in patient paclitaxel response. One overlap gene, RFX2, was functionally validated in a nerve cell model of paclitaxel response. Peripheral neuropathy is often dose-limiting toxicity induced by paclitaxel treatment. If physicians could predict which patients are more likely to experience this severe toxicity, lower doses or alternative treatments could be prescribed.

**Materials and Methods**

**Cytotoxicity assays**

HapMap LCLs from a population with Northern and Western European ancestry from Utah (HAPMAPPT01, CEU, n = 77), a Yoruba population in Ibadan, Nigeria (HAPMAPPT03, YRI, n = 87), and an African-American population from the Southwest of the United States (HAPMAPPT07, ASW, n = 83) were treated with 12.5 nmol/L paclitaxel and cytotoxicity was determined using an AlamarBlue (Invitrogen) cellular growth inhibition assay as described (22). The cytotoxicity phenotype used in the LCL GWAS was mean percentage survival at 12.5 nmol/L paclitaxel determined from 6 replicates from 2 independent experiments. Percentage survival values for each cell line were log$_2$-transformed before statistical analysis to form an approximately normal distribution in each population.

**LCL genome-wide meta-analysis**

A GWAS of paclitaxel-induced cytotoxicity was conducted on each of the 3 populations separately. Greater than 2 million SNPs from HapMap 2.27 [minor allele frequency (MAF) > 0.05 within the panel, no Mendelian errors and in Hardy–Weinberg equilibrium (P > 0.001)] were tested for association with paclitaxel cytotoxicity in each population, using the quantitative trait disequilibrium test total association model (23). To control for population structure in the admixed ASW population, local ancestry at each genotyped SNP locus was estimated using HAPMIX (24) and to increase genome coverage of the ASW, ungenotyped markers were imputed using BEAGLE (25) as previously described (26). Genomic control lambda ($\lambda_{GC}$) values (27) were calculated for the GWAS of each population. Studies with $\lambda_{GC}$ values greater than 1 were corrected for residual inflation of the test statistic by dividing the observed test statistic at each SNP by the $\lambda_{GC}$ (27), and then the corresponding $P$ values were carried through the meta-analysis.

Using the software METAL, we combined SNP $P$ values across the 3 population studies, taking into account a study-specific weight (sample size) and direction of effect (positive or negative $\beta$; ref. 28). This approach converted the direction of effect and $P$ value observed in each study into a signed $Z$-score, such that very negative $Z$-scores indicate a small $P$ value and an allele associated with higher drug sensitivity, whereas large positive $Z$-scores indicate a small $P$ value and an allele associated with higher drug resistance. $Z$-scores for each SNP were combined across studies in a weighted sum, with weights proportional to the square-root of the sample size for each study (28).

**Patient samples and GWAS**

Cancer and Leukemia Group B (CALGB) 40101 is a phase III trial comparing the efficacy of standard therapy cyclophosphamide and doxorubicin with single-agent paclitaxel...
as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary lymph nodes. All study participants were enrolled in CALGB 40101 and gave their additional consent to participate in the pharmacogenomic companion study (CALGB 60202), which has been published (3). All patient research met state, federal, and Institutional Review Board guidelines. Germline DNA was isolated from 1,040 patients on the paclitaxel arm of CALGB 40101 and genotyped using the Illumina 610-Quad platform as described previously (3). Following quality control analysis, genotypes were available for 520,679 SNPs. Principal component (PC) analysis identified 855 genetic Europeans that were used in a GWAS of sensory peripheral neuropathy (3). A dose-to-event analysis was conducted, with an event defined as grade 2 or greater sensory peripheral neuropathy. The Cox score test, powered for additive genetic effects, was used to test these marginal associations. Only SNPs with MAFs more than 0.05 in the patient population and in Hardy–Weinberg equilibrium in the CEU \( P > 0.001 \) were used in the LCL GWAS comparisons.

**Enrichment analysis**

We conducted a permutation resampling analysis (29) to test for an enrichment of cytotoxicity-associated SNPs (LCLs) among the paclitaxel-induced sensory peripheral neuropathy-associated SNPs (patients). To this end, the patient outcomes (cumulative dose and event indicator vectors) were randomly shuffled while keeping the genotype data fixed to preserve linkage disequilibrium. On the basis of this permutation replicate, the standardized Cox score statistics were recalculated for all the SNPs. This process was conducted 1,000 times. For each of the 1,000 permutation replicates, the number of SNPs that had \( P < 0.05 \) in the patient data, \( P < 0.001 \) in the LCL data, and the same direction of effect (the same allele associated with increased neuropathy and increased cytotoxicity) was calculated. The overlap distribution from the permutations was compared with the observed SNP overlap to generate an empirical \( P \) value, calculated as the proportion of permutations in which the number of LCL/patient overlap SNPs exceeds the observed number. To test the robustness of our findings, we calculated an empirical \( P \) value across a range of inclusion thresholds from \( P < 0.001 \) to \( P < 0.1 \). We also tested for enrichment of patient SNPs among the LCL SNPs by generating 1,000 randomized SNP sets the same size and MAF distribution as the observed LCL data at a range of \( P \) value thresholds to calculate empirical \( P \) values. In addition to the paclitaxel LCL cytotoxicity data, we compared the patient sensory peripheral neuropathy data with LCL cytotoxicity GWAS data from capetebit (30) and carboplatin (13) as negative controls.

To test for eQTL enrichment in the LCL patient, and LCL/patient overlap SNPs, we generated 10,000 randomized SNP sets each of the same size as the observed set of LCL cytotoxicity \( P < 0.001 \), patient neuropathy \( P < 0.05 \), or LCL/patient overlap SNPs. The randomized SNP sets were matched on MAF distribution of the observed list and sampled (without replacement) from the set of SNPs on the Illumina 610-Quad platform, similar to the method of Gamazon and colleagues (31). We grouped the platform SNPs into discrete MAF bins of a width of 5%, from which the SNPs used in the simulations were selected. For each of the 10,000 sets, we determined the number of eQTLs \( (P < 10^{-4}) \) and calculated an empirical \( P \) value for enrichment. The eQTLs were defined previously and are available in the SCAN database (21, 31).

**Filtering procedure for functional analysis**

First, we determined which of the LCL/patient overlap SNPs from the enrichment analysis were located in or near (within 2 kb) gene transcripts (dbSNP build 129, human genome assembly build 36). Eleven of 24 overlap SNPs were in or near genes and genotyping intensity plots for these SNPs in the patient data are available in Supplementary Fig. S1. Second, we determined which SNPs within genes were also eQTLs (31) and prioritized by which had the most target genes \( (P < 10^{-4}) \). We also tested whether the expression of the eQTL target genes associated with paclitaxel-induced cytotoxicity \( (P < 0.05) \) using previously published exon array data (32). A general linear model was constructed between gene expression and paclitaxel-induced cytotoxicity with growth rate (33) and population covariates. A Toeplitz covariance structure with 2 diagonal bands was used to allow for familal dependencies in the data as previously described (9).

**siRNA**

Neuroscreen-1 (NS-1) rat pheochromocytoma cells (Celomics Inc.) were maintained in NS-1 media (RPMI supplemented with 10% horse serum, 5% fetal calf serum and 1% L-glutamine). Cells were seeded at a density of \( 1 \times 10^{5} \) cells/ml on collagen I-coated plates and induced to differentiate by adding 20 ng/ml nerve growth factor (NGF, BD Biosciences) to the media 24 hours before transfection. Cells for cytotoxicity assays were plated in 96-well collagen I–coated plates, whereas cells for expression quantification and neurite-outgrowth assays were plated in 6-well collagen I–coated plates. PooleledRfx2 siRNA (25 nmol/L; Qiagen; S101639659, S101639666, S101639673, and S101639680) or nontargeting control siRNA (Qiagen; 1027292) was transiently transfected into the NS-1 cells using DharmaFECT Reagent #1 (Dharmacon). Quantitative reverse transcription PCR (qRT-PCR) was conducted for Rfx2 (Rn00501380_m1) and control gene Gapdh (4352338E) using TaqMan Gene Expression Assays (Applied Biosystems) 24 hours posttransfection in the neurite-outgrowth assays and 24, 48, 72, and 96 hours posttransfection in the cytotoxicity assays to assess Rfx2 knockdown in NS-1 cells. Expression of the potential Rfx2 target genes Cyp51 (Rn01526553_m1), Bach1 (Rn01477344_m1), and Cbna1 (Rn01644475_m1) was also measured by qRT-PCR at 24 hours post-siRfx2 transfection. Each qRT-PCR was run in duplicate and individual samples were run in triplicate on each plate. Percentage knockdown was calculated by dividing the relative Rfx2 expression levels in the siRfx2 sample by those in the nontargeting control sample.
Neurite-outgrowth assays
Twenty-four hours following siRNA transfection, transfection media was removed from the NS-1 cells and 0, 12.5, or 100 nmol/L paclitaxel in NS-1 media (supplemented with 20 ng/mL NGF) was added to either the siRfx2 or nontargeting control cells. After 24 hours in the presence of paclitaxel, phase-contrast images (>10) of the cells were taken using an Axiovert 200M inverted widefield fluorescence microscope (Zeiss). At least 500 cells per treatment in 6 randomly chosen fields were imaged and the longest neurite per cell was measured using ImageJ (34) software. The entire experiment was carried out in duplicate and mean neurite lengths were normalized relative to the 0 nmol/L drug treatment for each siRNA. Because tracing neurite lengths is somewhat qualitative, 2 scientists independently measured neurite lengths and the second scientist was blinded to siRNA/drug treatment. The mean of each set of measurements between the 2 scientists was assessed for significance by 2-way ANOVA (factors: siRNA treatment and drug treatment) to determine if the siRfx2 affected neurite length upon paclitaxel treatment.

NS-1 cytotoxicity assays
Twenty-four hours after siRNA transfection, transfection media was removed from the NS-1 cells and 0, 6.25, 12.5, 25, 50, or 100 nmol/L paclitaxel in NS-1 media (supplemented with 20 ng/mL NGF) in triplicate was added to either the siRfx2 or nontargeting control cells. After 72 hours of paclitaxel treatment, ATP levels were measured using the CellTiter-Glo assay (Promega) and percentage survival curves were generated. The entire experiment was done in duplicate and 2-way ANOVA was used to determine if the siRfx2 significantly affected overall cytotoxicity upon paclitaxel treatment.

Results
Enrichment of LCL cytotoxicity SNPs in patient sensory peripheral neuropathy SNPs
We conducted a genome-wide meta-analysis (see Materials and Methods) to test common SNPs for association with paclitaxel-induced cytotoxicity in LCLs. We compared the results from this analysis with those from clinical trial CALGB 40101, a GWAS of paclitaxel-induced sensory peripheral neuropathy in patients with breast cancer (3). Neither study produced genome-wide significant results (α < 0.05) nor did the very top SNPs match between the 2 studies (Fig. 1). However, through a permutation resampling analysis of the CALGB patient data, we found that the top sensory peripheral neuropathy-associated SNPs (P < 0.05) are significantly enriched for SNPs associated with paclitaxel-induced cytotoxicity in LCLs (P < 0.001) with consistent allelic directions of effect (Fig. 2; empirical P = 0.007). The observed enrichment of 24 SNPs between the LCL and patient studies is likely paclitaxel-specific, due to the sensory peripheral neuropathy SNPs not being enriched for either capecitabine- or carboplatin-induced cytotoxicity SNPs, which were tested as negative controls (Fig. 2). Positional information and effect sizes of all 24 overlap SNPs in the LCL and patient data can be found in Supplementary Table S1. When the inclusion thresholds for overlap SNPs were relaxed and when the LCL SNPs were tested for enrichment of patient SNPs, the significant overlap was present at a range of P value thresholds from 0.001 to 0.1, showing the robustness of our findings (Supplementary Table S2).

Enrichment of eQTLs in LCL/patient overlap SNPs
We tested the top paclitaxel-induced LCL cytotoxicity SNPs (P < 0.001) and the top paclitaxel-induced patient sensory peripheral neuropathy SNPs (P < 0.05) for eQTL

![Figure 1. Comparison of individual GWAS results. Left, paclitaxel-induced cytotoxicity in LCLs. Right, paclitaxel-induced sensory peripheral neuropathy in patients. White lines represent the overlap thresholds used in the primary enrichment analysis (P < 0.001 for LCLs and P < 0.05 for patients) and white triangles represent the 24 overlap SNPs at these thresholds.](clincancerres.aacrjournals.org)
enrichment because these were the thresholds used in the primary overlap analysis. We compared the observed number of eQTLs at these thresholds to the number of eQTLs in 10,000 randomly selected MAF-matched SNP sets (for details, see Materials and Methods). Neither cytotoxicity-associated SNPs nor neuropathy-associated SNPs alone were enriched for eQTLs (Fig. 3). However, we found that the 24 paclitaxel LCL/patient overlap SNPs at these thresholds are enriched for eQTLs when compared with MAF-matched SNP sets (empirical \(P = 0.0447\)), potentially revealing an important role for this functional class in paclitaxel toxicity.

Prioritization of LCL/patient overlap SNPs for functional analysis

First, we determined that 11 of 24 overlap SNPs from the enrichment analysis were located in or near (within 2 kb) gene transcripts (Table 1). The relationship of these 11 SNPs with paclitaxel-induced sensory peripheral neuropathy in patients and LCL cytotoxicity is shown in Supplementary Fig. S2. Next, we determined which of these 11 SNPs within genes were also eQTLs (31). Of the 8 eQTLs, we determined which had the most potential target genes at an arbitrary threshold of \(P < 10^{-4}\). The SNP in RFX2 had 18 target genes, more than any other of the 8 eQTLs. In addition, we tested the expression of the target genes for association with paclitaxel-induced cytotoxicity adjusted for growth rate (see Materials and Methods). We found that expression of 3 of the RFX2 target genes associated with paclitaxel-induced cytotoxicity (Table 1 and Supplementary Table S3); therefore, we pursued evaluating RFX2 in a model of neuropathy.

Functional validation of RFX2 in a paclitaxel-induced peripheral neuropathy model

We used neuroscreen (NS-1) cells, a subclone of the rat pheochromocytoma cell line PC-12 that has previously been used as a research model for chemotherapy-induced neuropathy (35, 36), to test Rfx2, the rat ortholog of RFX2, for functional involvement in paclitaxel response. Using siRNA, we decreased expression of Rfx2 resulting in increased sensitivity of NS-1 cells to paclitaxel, as measured by reduced neurite outgrowth and increased cytotoxicity (Fig. 4). The 3 RFX2 SNP target genes whose expression associated with paclitaxel-induced cytotoxicity in LCLs are CYP51A1, BACH1, and CBARA1 (Table 1; Fig. 5A–C, \(P < 0.05\)). We measured the expression of these 3 potential Rfx2 target genes upon knockdown of Rfx2 in NS-1 cells and found that the expression of 1 of 3 genes, Cyp51 (rat ortholog of CYP51A1), significantly decreased 24 hours posttransfection (\(P < 0.05\), which is the expected direction of effect based on the LCL expression versus cytotoxicity data (Fig. 5D).

Discussion

We conducted a GWAS of paclitaxel-induced cytotoxicity in LCLs and showed significant enrichment of the top cytotoxicity-associated SNPs in a clinical GWAS of paclitaxel-induced sensory peripheral neuropathy in patients with breast cancer. This robust enrichment shows that susceptibilities to increased cytotoxicity in LCLs and sensory peripheral neuropathy in patients with breast cancer likely have some genetic mechanisms in common and supports the role of LCLs as a preclinical model for paclitaxel toxicity studies. Furthermore, the top SNPs that overlap between the 2 studies were enriched for eQTLs. This eQTL enrichment

Figure 2. Patient paclitaxel-induced sensory peripheral neuropathy SNPs are enriched for SNPs associated with paclitaxel-induced cytotoxicity in LCLs. Distribution of chemotherapeutic-induced cytotoxicity SNP \(P < 0.001\) count in 1,000 permutations of neuropathy phenotype–genotype connections \(P < 0.05\). The dot is the observed SNP overlap at these thresholds. Of the 3 drug studies tested (paclitaxel, capecitabine, and carboplatin), only paclitaxel-induced cytotoxicity SNPs were significantly enriched in the patient GWAS (empirical \(P = 0.007\)).
Figure 3. SNPs associated with both patient paclitaxel-induced sensory peripheral neuropathy and LCL paclitaxel-induced cytotoxicity are enriched for eQTLs. Distribution of eQTL ($P < 10^{-4}$) count in 10,000 simulations, each matching the MAF distribution of either LCL paclitaxel SNPs ($P < 0.001$), patient paclitaxel SNPs ($P < 0.05$), or the set of 24 LCL/patient overlap SNPs at these $P$ value thresholds. Neither the LCL paclitaxel SNPs nor the patient paclitaxel SNPs alone were enriched for eQTLs, but the overlap SNP set between the 2 GWAS was enriched for eQTLs (empirical $P = 0.0447$).

Figure 4. Functional validation of RFX2 in paclitaxel response using a peripheral neuropathy cell model. A, representative micrographs comparing neurite lengths of NS-1 cells upon siRNA knockdown of Rfx2 and treatment with paclitaxel (×10 phase-contrast). B, relative gene expression 24 hours posttransfection in the 2 neurite length experiments. NTC, nontargeting control. C, decreased expression of Rfx2 causes decreased neurite length of differentiating NS-1 cells ($P < 10^{-4}$) 24 hours post-paclitaxel treatment (48 hours posttransfection). Error bars represent the SEM of the longest relative neurite length of at least 500 cells in each of 2 independent experiments. D, relative gene expression 24 to 96 hours posttransfection in the 2 cytotoxicity experiments. E, decreased expression of Rfx2 causes decreased survival (increased cytotoxicity, $P < 10^{-4}$) of differentiating NS-1 cells measured by CellTiter-Glo 72 hours post-paclitaxel treatment (96 hours posttransfection). Error bars represent the SEM of survival in 2 independent experiments with 3 replicates each.
indicates that SNPs associated with paclitaxel-induced toxicity phenotypes may be functioning through gene regulatory mechanisms. Interestingly, neither GWAS alone was enriched for eQTLs. Thus, our integration method may be reducing noise and revealing important functional SNPs. An enrichment of eQTLs has previously been shown in SNPs associated with 6 other chemotherapeutic drugs, which indicates that susceptibility to these drugs may depend on subtle gene expression differences across individuals (31).

The enrichment analyses were likely affected by the different linkage disequilibrium patterns among the populations studied. The LCL GWAS was a meta-analysis of African, African American, and European populations, whereas the patient GWAS was conducted in Europeans. In the meta-analysis, SNPs that are associated with cytotoxicity in all populations are prioritized over those associated in only one of the populations. We may have missed identifying European-specific overlap alleles. However, because the population linkage disequilibrium patterns differ and because African populations have shorter linkage disequilibrium blocks, overlap SNPs are more likely to be functional SNPs rather than SNPs that simply tag a functional locus (37).

We functionally assessed the involvement of one overlap eQTL, RFX2, in the NS-1 neuropathy cell model. Paclitaxel has previously been shown to decrease neurite outgrowth in the parent clone of the NS-1 cell line (36). Here, we showed that decreased expression of Rfx2 sensitizes NS-1 cells to paclitaxel by reducing neurite outgrowth and survival. This result validates our approach by showing that patient neuropathy and LCL cytotoxicity overlap analyses can reveal genes mechanistically involved in paclitaxel response. Although most previous work on RFX2 in mammalian cells describes its role in spermatogenesis (38, 39), several studies point to a potential role for the protein in sensory neurons. RFX2 and the related protein RFX1 have been shown to directly bind and regulate the transcription of ALMS1 (40). Mutations in ALMS1 cause the rare genetic disorder Alstrom syndrome, which is characterized by neurosensory degeneration, metabolic defects, and cardiomyopathy (40). In addition, the regulatory factor X

Table 1. Paclitaxel-induced LCL cytotoxicity (P < 0.001) and paclitaxel-induced patient sensory peripheral neuropathy (P < 0.05) overlap SNPs located in genes

<table>
<thead>
<tr>
<th>SNP</th>
<th>LCL cytotoxicity P value</th>
<th>Patient sensory peripheral neuropathy P value</th>
<th>Gene</th>
<th>eQTL</th>
<th>Number of target genes</th>
<th>Target genes associated with LCL paclitaxel-induced cytotoxicity* (P &lt; 0.05)</th>
</tr>
</thead>
<tbody>
<tr>
<td>rs7254081</td>
<td>5.9E-04</td>
<td>4.8E-02</td>
<td>RFX2</td>
<td>yes</td>
<td>18</td>
<td>CYP51A1, BACH1, CBARA1</td>
</tr>
<tr>
<td>rs7642318</td>
<td>2.2E-04</td>
<td>3.9E-02</td>
<td>TMEM44</td>
<td>yes</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>rs10933663</td>
<td>4.0E-04</td>
<td>2.1E-02</td>
<td>TMEM44</td>
<td>yes</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>rs802545</td>
<td>9.2E-04</td>
<td>3.1E-02</td>
<td>DIS3</td>
<td>yes</td>
<td>3</td>
<td></td>
</tr>
<tr>
<td>rs4782010</td>
<td>5.5E-04</td>
<td>3.5E-02</td>
<td>XLYT1</td>
<td>yes</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>rs11111359</td>
<td>7.9E-04</td>
<td>6.7E-03</td>
<td>C12orf42</td>
<td>yes</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>rs7306825</td>
<td>7.2E-04</td>
<td>9.3E-03</td>
<td>C12orf42</td>
<td>yes</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>rs8069866</td>
<td>1.1E-04</td>
<td>4.5E-02</td>
<td>RICH2</td>
<td>yes</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>rs4868011</td>
<td>8.2E-04</td>
<td>4.2E-02</td>
<td>KCNIP1</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs10778237</td>
<td>9.3E-04</td>
<td>1.3E-02</td>
<td>C12orf42</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>rs323285</td>
<td>5.1E-04</td>
<td>3.7E-02</td>
<td>KIAA1328</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Adjusted for growth rate.
transcription factors present in Caenorhabditis elegans and Drosophila, which are called DAF-19 and RFX, respectively, regulate ciliated sensory neuron differentiation (41, 42).

Upon knockdown of Rfx2 in NS-1 cells, the potential target gene Cyp51 also decreased expression, which was the expected direction of effect based on the preliminary gene expression analysis in LCLs. However, CYP51A1 does not contain an X-box RFX-binding domain (43) in the promoter region (2 kb upstream of the transcription start site), which means it is unlikely a direct target of RFX2 and may instead be further downstream in the pathway. Alternatively, RFX2 could be regulating an enhancer of CYP51A1 that is further outside the gene region. CYP51A1 is a member of the cytochrome P450 superfamily of enzymes, which catalyze many reactions involved in the metabolism of drugs and endogenous compounds. Specifically, CYP51A1 is known to participate in the synthesis of cholesterol (44). CYP51A1 has not been previously implicated in paclitaxel metabolism (45).

In the CALGB GWAS, one of the top SNPs that associated with patient paclitaxel-induced sensory peripheral neuropathy (rs10771973, \(P = 2.6 \times 10^{-6}\)) is located in FGDR (3). Mutations in FGDR can cause the congenital peripheral neuropathy Charcot–Marie–Tooth disease type 4H, and thus the gene is a plausible candidate for involvement in variation in peripheral neuropathy induced by paclitaxel. This SNP association was replicated in a second cohort of self-reported White patients with breast cancer (\(n = 154; P = 0.013\)) and in a cohort of self-reported African American patients with breast cancer (\(n = 117; P = 6.7 \times 10^{-6}\), ref. 3). However, this SNP was not associated with paclitaxel-induced cytotoxicity in LCLs (\(P = 0.65\)). FGDR is not expressed in LCLs (21), and thus the SNP is not expected to function in this model system. While our integrative approach can reveal variants and genes acting in paclitaxel response in both patients and LCLs, it does not identify genes potentially acting in patients that are not expressed in LCLs.

Effectively, LCLs have been used as an additional cohort to study the pharmacogenomics of various chemotherapeutics (16–19) because limited resources and in vivo confounders make obtaining large, homogeneous patient cohorts difficult. Here, we saw greater SNP overlap than expected by chance between SNPs associated with paclitaxel-induced cytotoxicity in LCLs and SNPs associated with paclitaxel-induced sensory peripheral neuropathy in patients at multiple \(P\) value thresholds, which confirms a role for the LCL model in the analysis of at least a subset of genes involved in patient neurotoxicity. This significant enrichment among a relatively large number of top SNPs is consistent with an underlying polygenic architecture for paclitaxel-induced toxicity. Functional siRNA studies in the NS-1 neuropathy model validated the involvement of RFX2 in paclitaxel toxicity, supporting our multi-gene hypothesis. Our novel integrative enrichment approach that combines clinical and LCL GWAS results can be used to expand patient cohort sizes for any drug phenotype of interest, including other toxicities, such as neutropenia, to find genes of potential impact that can be studied in cellular models.

Disclosure of Potential Conflicts of Interest

E.P. Winer has a Commercial Research Grant from Roche. No potential conflicts of interest were disclosed by the other authors. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Cancer Institute (NCI).

Authors' Contributions


Writing, review, and/or revision of the manuscript: H.E. Wheeler, E.R. Gamazon, C. Wing, R.M. Baldwin, K. Owzar, C. Jiang, H. Zembutsu, E. Winer, C. Huds, L.N. Shulman, M.J. Ratain, D.L. Kroetz, N.J. Cox, M.E. Dolan

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): C. Wing, C. Huds

Study supervision: H.E. Wheeler, C. Huds, L.N. Shulman, M.E. Dolan

Acknowledgments

The authors thank the Pharmacogenomics of Anticancer Agents Research LCL core for maintaining and distributing LCLs.

Grant Support

This study is supported by NIH/NCI Cancer Biology Training grant T32CA099594 and National Research Service Award F32CA165823 (to H. E. Wheeler), NIH/National Institute of General Medical Sciences (NIGMS) Pharmacogenomics of Anticancer Agents grant U01GM61393 (to M.J. Ratain, N.J. Cox, M.E. Dolan, and K. Owzar), NIH/NIGMS Pharmacogenetics of Membrane Transporters grant 1U01GM61390 (to D.L. Kroetz), University of Chicago SPORE Grant NCI P50CA125183 (to M.E. Dolan), NIH/NCI Medical Oncology Training grant T32CA099566 (to U.O. Njijn), and the Biobank Japan Project funded by the Japanese Ministry of Education, Culture, Sports, Science and Technology. This work is part of the NIH Pharmacogenomics Research Network-RIKEN Center for Genomic Medicine Global Alliance.

The research for CALGB 60202 and 40101 was supported, in part, by grants from the NCI (CA31946) to the CALGB (Monica M. Bertagnolli) and to the CALGB Statistical Center (Daniel J. Sargent, CA33601).

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received August 7, 2012; revised November 1, 2012; accepted November 8, 2012; published OnlineFirst November 30, 2012.

References


# Integration of Cell Line and Clinical Trial Genome-Wide Analyses Supports a Polygenic Architecture of Paclitaxel-Induced Sensory Peripheral Neuropathy

Heather E. Wheeler, Eric R. Gamazon, Claudia Wing, et al.


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/1078-0432.CCR-12-2618</th>
</tr>
</thead>
<tbody>
<tr>
<td>Supplementary Material</td>
<td>Access the most recent supplemental material at: <a href="http://clincancerres.aacrjournals.org/content/suppl/2012/11/30/1078-0432.CCR-12-2618.DC1">http://clincancerres.aacrjournals.org/content/suppl/2012/11/30/1078-0432.CCR-12-2618.DC1</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 44 articles, 16 of which you can access for free at: <a href="http://clincancerres.aacrjournals.org/content/19/2/491.full.html#ref-list-1">http://clincancerres.aacrjournals.org/content/19/2/491.full.html#ref-list-1</a></th>
</tr>
</thead>
<tbody>
<tr>
<td>Citing articles</td>
<td>This article has been cited by 7 HighWire-hosted articles. Access the articles at: <a href="http://clincancerres.aacrjournals.org/content/19/2/491.full.html#related-urls">http://clincancerres.aacrjournals.org/content/19/2/491.full.html#related-urls</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, contact the AACR Publications Department at <a href="mailto:permissions@aacr.org">permissions@aacr.org</a>.</td>
</tr>
</tbody>
</table>